Analyzing Lifecore Biomedical (NASDAQ:LFCR) & ALIOF (OTCMKTS:ALIOF)

ALIOF (OTCMKTS:ALIOF) and Lifecore Biomedical (NASDAQ:LFCR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ALIOF and Lifecore Biomedical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALIOF	0	0	0	0	0.00
Lifecore Biomedical	1	2	1	0	2.00

Lifecore Biomedical has a consensus target price of $6.50, indicating a potential upside of 39.78%. Given Lifecore Biomedical’s stronger consensus rating and higher probable upside, analysts plainly believe Lifecore Biomedical is more favorable than ALIOF.

Profitability

This table compares ALIOF and Lifecore Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ALIOF	N/A	N/A	N/A
Lifecore Biomedical	-29.93%	N/A	-16.16%

Institutional and Insider Ownership

83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ALIOF and Lifecore Biomedical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALIOF	N/A	N/A	N/A	N/A	N/A
Lifecore Biomedical	$128.87 million	1.37	-$40.50 million	($1.07)	-4.35

ALIOF has higher earnings, but lower revenue than Lifecore Biomedical.

Summary

Lifecore Biomedical beats ALIOF on 6 of the 8 factors compared between the two stocks.

About ALIOF

Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.